Although α-amylase is the choice of target to manage postprandial hyperglycemia, inhibitors of this enzyme may get absorbed into the systemic circulation and modulate proteins involved in the pathogenesis of diabetes mellitus. Hence, the present study aimed to identify α-amylase inhibitors from Duranta repens via in silico and in vitro and predict their role in the modulation of multiple pathways involved in diabetes mellitus.
α-amylase inhibitory activity of hydroalcoholic extract/fractions (s) and pure compounds from D. repens was performed using in vitro enzyme inhibitory assay. Multiple open-source databases and published literature were used to retrieve reported phytoconstituents present in D. repens and their targets. The network was constructed between α-amylase inhibitors, modulated proteins, and expressed pathways. Further, hit molecules were also confirmed for their potency to inhibit α-amylase using in silico molecular docking and in vitro enzyme inhibitory assay. The glucose uptake assay was performed to assess the effect of hydrolcoholic extract/fraction(s) using rat hemidiaphragm.
Fraction rich in flavonoids showed the highest α-amylase inhibitory activity with a IC50 of 644.29 ± 4.36 µg/ml compared to other fractions. PI3K-Akt signaling pathway and p53 signaling pathway were predicted to be primarily modulated in the compound-protein-pathway network. Similarly, scutellarein was predicted as lead hit based on α-amylase inhibitory action, binding affinity, and regulated pathways. Further, α-amylase inhibitors were also predicted to modulate the pathways involved in diabetes complications like AGE-RAGE and FoxO signaling pathway. Fraction rich in flavonoids showed the highest glucose uptake in rat hemidiaphragm with an effective concentration of 534.73 ± 0.79 µg/ml.
The α-amylase inhibitors from D. repens may not be limited within the gastrointestinal tract to inhibit α-amylase but may get absorbed into the systemic circulation and modulate multiple pathways involved in the pathogenesis of diabetes mellitus to produce synergistic/additive effect.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Data will be provided in case of a request.
Chemical Entities of Biological Interest
- IC50 :
Inhibitory Concentration 50
Indian Council of Medical Research -National Institute of Traditional Medicine
Kyoto Encyclopedia of Genes and Genomes
Prediction of Activity Spectra for Substances
PhytoChemical Interactions DB
Protein Data Bank
Protein tyrosine phosphatase 1B
Research Collaboratory for Structural Bioinformatics
Search Tool for the Retrieval of Interacting Genes/Proteins
Type 2 Diabetes Mellitus
de Souza PM, de Oliveira Magalhães P. Application of microbial α-amylase in industry - A review. Braz J Microbiol. 2010;41(4):850–61. https://doi.org/10.1590/S1517-83822010000400004.
Telagari M, Hullatti K. In-vitro α-amylase and α-glucosidase inhibitory activity of Adiantum caudatum Linn. and Celosia argentea Linn. extracts and fractions. Indian J Pharmacol. 2015;47(4):425–9. https://doi.org/10.4103/0253-7613.161270.
Min SW, Han JS. Polyopes lancifolia extract, a potent α-Glucosidase Inhibitor, Alleviates Postprandial Hyperglycemia in diabetic mice. Prev Nutr Food Sci. 2014;19(1):5–9. https://doi.org/10.3746/pnf.2014.19.1.005.
Reuser AJ, Wisselaar HA. An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus. Eur J Clin Invest. 1994;24(S3):19–24. https://doi.org/10.1111/j.1365-2362.1994.tb02251.x.
Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;12(10):566–92. https://doi.org/10.1038/nrendo.2016.86.
Sacks DB, McDonald JM. The pathogenesis of type II diabetes mellitus. A polygenic disease. Am J Clin Pathol. 1996;105(2):149–56. https://doi.org/10.1093/ajcp/105.2.149.
Wang X, Xu X, Tao W, Li Y, Wang Y, Yang L. A systems biology approach to uncovering pharmacological synergy in herbal medicines with applications to cardiovascular disease. Evid Based Complement Alternat Med. 2012;2012:519031. https://doi.org/10.1155/2012/519031.
Subsongsang R, Jiraungkoorskul W. An Updated Review on Phytochemical Properties of “Golden Dewdrop” Duranta erecta. Pharmacogn Rev. 2016;10(20):115–7. https://doi.org/10.4103/0973-7847.194042.
Rauter AP, Martins A, Borges C, et al. Antihyperglycaemic and protective effects of flavonoids on streptozotocin-induced diabetic rats. Phytother Res. 2010;24(S2):133–8. https://doi.org/10.1002/ptr.3017.
Agrawal R, Sethiya NK, Mishra SH. Antidiabetic activity of alkaloids of Aerva lanata roots on streptozotocin-nicotinamide induced type-II diabetes in rats. Pharm Biol. 2013;51(5):635–42. https://doi.org/10.3109/13880209.2012.761244.
Ong KW, Hsu A, Song L, Huang D, Tan BK. Polyphenols-rich Vernonia amygdalina shows anti-diabetic effects in streptozotocin-induced diabetic rats. J Ethnopharmacol. 2011;133(2):598–607. https://doi.org/10.1016/j.jep.2010.10.046.
Zheng T, Shu G, Yang Z, Mo S, Zhao Y, Mei Z. Antidiabetic effect of total saponins from Entada phaseoloides (L.) Merr. in type 2 diabetic rats. J Ethnopharmacol. 2012;139(3):814–21. https://doi.org/10.1016/j.jep.2011.12.025.
Ponnusamy S, Ravindran R, Zinjarde S, Bhargava S, Ravi Kumar A. Evaluation of traditional Indian antidiabetic medicinal plants for human pancreatic amylase inhibitory effect in vitro. Evid Based Complement Alternat Med. 2011;2011:515647. https://doi.org/10.1155/2011/515647.
Iqbal K, Malik A, Mukhtar N, Anis I, Khan SN, Choudhary MI. Alpha-glucosidase inhibitory constituents from Duranta repens. Chem Pharm Bull (Tokyo). 2004;52:785–9. https://doi.org/10.1248/cpb.52.785.
Khanal P, Patil BM. α–Glucosidase inhibitors from Duranta repens modulate p53 signaling pathway in diabetes mellitus. Adv Tradit Med (ADTM). 2020. https://doi.org/10.1007/s13596-020-00426-w.
Cos P, Vlietinck AJ, Berghe DV, Maes L. Anti-infective potential of natural products: how to develop a stronger in vitro ‘proof-of-concept.’ J Ethnopharmacol. 2006;106(3):290–302. https://doi.org/10.1016/j.jep.2006.04.003.
Dassault Systèmes BIOVIA, Discovery S. 2019, San Diego: DassaultSystèmes, 2019.
Poroikov VV, Filimonov DA, Ihlenfeldt WD, Gloriozova TA, Lagunin AA, Borodina YV, et al. PASS biological activity spectrum predictions in the enhanced open NCI database browser. J Chem Inf Comput Sci. 2003;43(1):228–36. https://doi.org/10.1021/ci020048r.
Lagunin A, Ivanov S, Rudik A, Filimonov D, Poroikov V. DIGEP-Pred: Web service for in silico prediction of drug-induced gene expression profiles based on structural formula. Bioinformatics. 2013;29(16):2062–3. https://doi.org/10.1093/bioinformatics/btt322.
Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362-8. https://doi.org/10.1093/nar/gkw937.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504. https://doi.org/10.1101/gr.1239303.
Halgren TA. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem. 1996;17:490–519. https://doi.org/10.1002/(SICI)1096-987X(199604)17:5/6490::AID-JCC1>3.0.CO;2-P.
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–91. https://doi.org/10.1002/jcc.21256.
Kumar M, Prasad SK, Hemalatha S. In Vitro study on glucose utilization capacity of bioactive fractions of Houttuynia cordata in isolated rat hemidiaphragm and its major phytoconstituent. Adv Pharmacol Sci. 2016;2016:2573604. https://doi.org/10.1155/2016/2573604.
Chandran U, Mehendale N, Tillu G, Patwardhan B. Network pharmacology of ayurveda formulation Triphala with special reference to anti-cancer property. Comb Chem High Throughput Screen. 2015;18(9):846–54. https://doi.org/10.2174/1386207318666151019093606.
Khanal P, Patil BM. Gene set enrichment analysis of alpha-glucosidase inhibitors from Ficus benghalensis. Asian Pac J Trop Biomed. 2019;9(6):263–70. https://doi.org/10.4103/2221-1691.260399.
Khanal P, Patil BM, Mandar BK, Dey YN, Duyu T. Network pharmacology-based assessment to elucidate the molecular mechanism of anti-diabetic action of Tinospora cordifolia. Clin Phytosci. 2019;5:35. https://doi.org/10.1186/s40816-019-0131-1.
Gene Ontology Unifying Biology. GO enrichment analysis. [Internet] Available at: http://geneontology.org/docs/go-enrichment-analysis/. Accessed 4 May 2020.
Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14(11):1483–96. https://doi.org/10.7150/ijbs.27173.
Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res. 2005;36(3):197–209. https://doi.org/10.1016/j.arcmed.2005.01.003.
Khorami SA, Movahedi A, Sokhini AM. PI3K/AKT pathway in modulating glucose homeostasis and its alteration in Diabetes. Int J Biol Sci. 2018;14(11):1483–96. https://doi.org/10.7150/ijbs.27173.
Strycharz J, Drzewoski J, Szemraj J, Sliwinska A. Is p53 Involved in Tissue-Specific Insulin Resistance Formation? Oxid Med Cell Longev. 2017;2017:9270549. https://doi.org/10.1155/2017/9270549.
Talevi A. Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective. Front Pharmacol. 2015;6:205. https://doi.org/10.3389/fphar.2015.00205.
Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med. 2018;7(1):3. https://doi.org/10.1186/s40169-017-0181-2.
Nickerson HD, Dutta S. Diabetic complications: current challenges and opportunities. J Cardiovasc Transl Res. 2012;5(4):375–9. https://doi.org/10.1007/s12265-012-9388-1.
Zhang L, Chen Q, Li L, Kwong JS, Jia P, Zhao P, Wang W, Zhou X, Zhang M, Sun X. Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis. Sci Rep. 2016;6:32649. https://doi.org/10.1038/srep32649.
Tran ND, Hunter SK, Yankowitz J. Oral hypoglycemic agents in pregnancy. Obstet Gynecol Surv. 2004;59(6):456–85. https://doi.org/10.1097/00006254-200406000-00024.
KEGG Pathway [hsa04933.]. AGE-RAGE signaling pathway in diabetic complications - Homo sapiens (human). Available at: https://www.genome.jp/dbget-bin/www_bget?hsa04933. Accessed 4 Dec 2019.
KEGG Pathway [hsa04068]. FoxO signaling pathway - Homo sapiens (human). Available at: https://www.genome.jp/dbget-bin/www_bget?pathway+hsa04068. Accessed 4 Dec 2019.
KEGG Pathway [map04211]. Longevity regulating pathway. Available at: https://www.genome.jp/dbget-bin/www_bget?map04211. Accessed 4 Dec2019.
Disney A. KeyLines FAQs: Social network analysis. Cambridge intelligence. 2014. Available at: https://cambridge-intelligence.com/keylines-faqs-social-network-analysis/. Accessed 8 Dec 2019.
Max Planck Institute for Informatics. Network analyzer settings. 2018. Available at: https://med.bioinf.mpi-inf.mpg.de/netanalyzer/help/2.7/#neighborConn. Accessed 8 Dec 2019.
Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004;64(7):2627–33. https://doi.org/10.1158/0008-5472.can-03-0846.
Richter EA, Hargreaves M, Exercise. GLUT4, and skeletal muscle glucose uptake. Physiol Rev. 2013;93(3):993–1017. https://doi.org/10.1152/physrev.00038.2012.
Mogyorósi A, Ziyadeh FN. GLUT1 and TGF-beta: the link between hyperglycaemia and diabetic nephropathy. Nephrol Dial Transplant. 1999;14(12):2827–9. https://doi.org/10.1093/ndt/14.12.2827.
Kung CP, Murphy ME. The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol. 2016;231(2):R61-75. https://doi.org/10.1530/JOE-16-0324.
The authors are thankful to Principal KLE College of Pharmacy, Belagavi for providing necessary facilities and Head of Department of Pharmacology and Toxicology, KLE College of Pharmacy, Belagavi, for supporting to complete the work. Pukar Khanal is also thankful to Ms. Taaza Duyu for her assistance during the enzyme inhibitory activity.
This work has not received any funds from national and international agencies.
Conflict of interest
There are no conflicts of interest to declare.
Consent for publication
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Khanal, P., Patil, B.M. Gene ontology enrichment analysis of α-amylase inhibitors from Duranta repens in diabetes mellitus. J Diabetes Metab Disord (2020). https://doi.org/10.1007/s40200-020-00554-9
- Duranta repens
- Network pharmacology